Key facts
- It has raised $13.7M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Innoangel Fund, Peiyang Begonia Fund, Dalton Venture, Tianjin Venture Capital, Beijing Shangshi Investment Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Meihao Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Meihao Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Meihao Biotechnology
Developer of industrial enzyme preparations intended for industrial clients. The company engages in the research and development of industrial enzyme preparations, the manufacturing of bio-based materials, the research and development of new materials technology, and sales of bio-based materials, providing customers with environmentally friendly industrial enzyme preparation solutions.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Meihao Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Meihao Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Meihao Biotechnology in its N-PORT filings yet. We sweep new filings monthly.